test

Join us for our BRAND NEW! Mastering Triglyceride Science Master’s Course – a 1-day master’s level course designed to address knowledge, competence, and practice gaps in managing hypertriglyceridemia and its associated pathophysiological manifestation and to provide you with improved proficiency on the complexities of severe hypertriglyceridemia, and targets of therapy. 

The course will review the latest evidence and research on triglyceride disorders, targets of therapy, and existing and novel triglyceride-lowering therapies. Participants will be expected to improve their severe hypertriglyceridemia knowledge and competence, expand the depth of their understanding of lipid science, and help their patients make informed decisions about lipid therapies to reduce the risk of extreme complications related to severe hypertriglyceridemia.

2024 Course Dates:


TARGET AUDIENCE

The Mastering Triglyceride Science: An In-Depth Master’s Course is designed for an audience of lipidologists and lipid specialists, researchers, and other specialists with advanced knowledge and experience in preventive cardiology and/or lipid science.

This course will be held in conjunction with the NLA’s 2024 Scientific Sessions and 2024 Fall Clinical Lipid Update as a pre-conference activity.

At the conclusion of this activity, participants should be able to:

  • Discuss strategies for the management of patients with lipid disorders.
  • Recognize the prevalence of triglyceride-rich remnant lipoproteins in ASCVD.
  • Discuss treatment options for hypertriglyceridemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD.
  • Outline appropriate therapy options for high CVD risk patients with elevated triglyceride levels.
  • Identify the clinical and genetic attributes, available diagnostic tools, and screening practices to aid the identification of individuals with chylomicronemia syndrome.
  • Explain the role of genetic testing in the identification of familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia (MCM).
  • Outline appropriate therapy options for patients with chylomicronemia syndrome and multifactorial chylomicronemia.
  • Discuss strategies to improve the knowledge, skills, or performance of the healthcare team.

The Lipid Panel – Mastering Triglyceride Science: An In-Depth Master’s Course
May 29, 2024
OBJECTIVES & ACCREDITATION

Program Overview
The Mastering Triglyceride Science: An In-Depth Master’s course is a master’s level course series addressing knowledge, competence, and practice gaps in managing hypertriglyceridemia and its associated pathophysiological manifestation and to provide lipid specialists with improved proficiency on the complexities of severe hypertriglyceridemia, and targets of therapy.

Target Audience
This activity is intended for lipidologists, allied health specialists, researchers, and other specialists with advanced knowledge and experience in preventive cardiology and/or lipid science.

Target Audience
Live Course Activity
Knowledge

Educational Objective(s)

  • Discuss strategies for the management of patients with lipid disorders.
  • Recognize the prevalence of triglyceride-rich remnant lipoproteins in ASCVD.
  • Discuss treatment options for hypertriglyceridemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD.
  • Outline appropriate therapy options for high CVD risk patients with elevated triglyceride levels.
  • Identify the clinical and genetic attributes, available diagnostic tools, and screening practices to aid the identification of individuals with chylomicronemia syndrome.
  • Explain the role of genetic testing in the identification of familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia (MCM).
  • Outline appropriate therapy options for patients with chylomicronemia syndrome and multifactorial chylomicronemia.
  • Discuss strategies to improve the knowledge, skills, or performance of the healthcare team.

CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at lipid.org/cme. The deadline to claim credit is June 29, 2024. Questions related to this content should be sent to cme@lipid.org.

COMMERCIAL SUPPORT
This activity is being supported from funding by Ionis Pharmaceuticals, Inc.

CREDIT DESIGNATION

 

CME/CE credit provided by the National Lipid Association

 

In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this internet enduring activity for a maximum of 8.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Pharmacists
Universal Activity Number UAN JA0007192-0000-24-011-L01-P (Knowledge)
This Activity has been approved for 8.0 contact hour(s) (0.8 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
The maximum number of hours awarded for this CE activity is 7.6 contact hours.

 

DISCLOSURE INFORMATION FACULTY, PLANNERS, & REVIEWERS

Zahid Ahmad, MD
Consultant: Amryt
Research: US Department of Defense, National Institute of Health, Ionis

Venkata Akshintala, MD
Co-founder: Solv Endotherapy Inc, Origin Endoscopy Inc
Consultant: Oympus Medical Inc

Christie Ballantyne, MD
Grant/Research Support: Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, ADA
Consultant: 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken*, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam*, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic

Alan Brown, MD
Advisory Board: Ionis, Esperion, New Amsterdam, Regeneron, Novartis, Merck, Amgen
Speaker: Esperion, Regeneron, Amgen

Abhimanyu Garg, MD
Consultant: Amryt, Arrowhead, Regeneron
Research: Amryt, Regeneron, Intercept

Nivedita Patni, MD
Advisory Board: Amryt Pharmaceuticals Inc
Consultant: Ionis Pharmaceuticals

 

Staff Disclosures

NLA Staff
Has nothing to disclose.

 

NLA ICE Committee Reviewers

Peter Jones
Has nothing to disclose.

 

Susan Demeter
Has nothing to disclose.

 

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Zahid Ahmad, MD

Course Chair
Associate Professor of Internal Medicine
Lipid Section, Division of Endocrinology
UT Southwestern Medical Center
Dallas, TX

Venkata S. Akshintala, MD

Assistant Professor
Program Director, Medical Pancreatology and Therapeutic Endoscopy Fellowships
Johns Hopkins University School of Medicine
Baltimore, MD

Alan S. Brown, MD MHA FACC FASPC FAHA MNLA

Director, Lipid Clinic
Advocate Lutheran General Hospital
Clinical Professor of Medicine
Rosalind Franklin School of Medicine and Science
Chicago, IL

Nivedita Patni, MD

Director, Pediatric Endocrinology Fellowship
Assistant Professor of Pediatrics
Division of Pediatric Endocrinology
UT Southwestern Medical Center
Dallas, TX

Abhimanyu Garg, MD

Professor of Internal Medicine, Chief, Section of Nutrition and Metabolic Diseases, Division of Endocrinology
UT Southwestern Medical Center
Dallas, TX

* The live agenda will be updated throughout the planning process as new information and outcomes data is released.

Wednesday, May 29, 2024

Day 1

7:30 AM - 8:00 AM Welcome | Pre-test
8:00 AM - 9:00 AM Physiology and Disorders Associated with Triglyceride Synthesis and Secretion, Lipolysis/Clearance, and Remnant Removal Abhimanyu Garg, MD
9:00 AM - 9:20 AM Question and Answer
9:20 AM - 9:40 AM MCS Zahid Ahmad, MD, FNLA
9:40 AM - 10:00 AM FCS Nivedita Patni, MD
10:00 AM - 10:20 AM Question and Answer
10:20 AM - 10:30 AM Break
10:30 AM - 10:50 AM Lipodystrophies Abhimanyu Garg, MD
10:50 AM - 11:05 AM Question and Answer
11:05 AM - 11:45 AM Mechanism, Diagnosis, and Treatment of Hypertriglyceridemic Pancreatitis Venkata S. Akshintala, M.D. (May), Ellie Afghani, MD, MPH (September)
11:45 AM - 12:00 PM Question and Answer
12:00 PM - 12:25 PM Abstract Presentations
12:25 PM - 1:15 PM Lunch
1:15 PM - 1:45 PM Mechanism, Diagnosis, and Treatment of Increased ASCVD Risk from Remnant Lipoproteins Alan S. Brown, MD, MNLA
1:45 PM - 2:05 PM Question and Answer
2:05 PM - 2:35 PM Current and Future Pharmacologic Treatments for Hypertriglyceridemia Zahid Ahmad, MD, FNLA
2:35 PM - 2:45 PM Question and Answer
2:45 PM - 3:00 PM Break
3:00 PM - 4:00 PM Interactive Patient Cases | Roundtable Discussion | Tips & Tricks All Speakers
4:00 PM - 4:20 PM Post-Test